Clinical Trial

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection. The goals of this study are to learn: * If taking MK-8527 once a month works to prevent HIV-1 infection better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day * About the safety of MK-8527 and if people tolerate it
Protocol Amendment History 24 amendments
This ClinicalTrials.gov record has been amended 24 times since 2025-07-08; most recent amendment 2026-07-17.
Status change: Not Yet Recruiting → Recruiting 2025-11-11
Trial Details
NCT Number NCT07071623
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Enrollment 4,580 participants
Start Date 2025-11-10
Primary Completion 2027-10-18 (estimated)
Study Completion 2027-10-18 (estimated)
Updated on ClinicalTrials.gov 2026-08-14